Showing results (1-10 of 780) with videos related to
Sort By:
Pageof 78
Journal of Psychopharmacology (Oxford, England)|October 7, 2010
Mortality in schizophrenia: a measurable clinical endpointChris J Bushe, Mark Taylor, Jari HaukkaAnnals of General Psychiatry|April 3, 2007
Intramuscular Olanzapine - a UK case series of early casesChris J Bushe, Mark Taylor, Mathew MathewThe American Journal of Psychiatry|March 3, 2011
A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophreniaJari Tiihonen, Jari Haukka, Mark Taylor, et al.Acta Ophthalmologica|April 13, 2026
Hormonal replacement therapy in postmenopausal women ≥50 years is associated with the incidence of glaucoma: Evidence from 6576 females in FinlandSirpa Loukovaara, Jari HaukkaActa Ophthalmologica|January 3, 2021
Intravitreal anti-VEGF therapy is not associated with a higher risk of all-cause mortality in patients with macular oedema caused by posterior segment vascular diseasesSirpa Loukovaara, Jari HaukkaClinical Ophthalmology (Auckland, N.Z.)|August 28, 2018
Repair of primary RRD - comparing pars plana vitrectomy procedure with combined phacovitrectomy with standard foldable intraocular lens implantationSirpa Loukovaara, Jari HaukkaCanadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|December 22, 2010
Schizophrenia and cancer: in 2010 do we understand the connection?Chris J Bushe, Richard HodgsonJournal of Central Nervous System Disease|July 18, 2013
Atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder. Systematic review of review papers 2009-2011. An update for cliniciansChris J Bushe, Nicola SavillChild and Adolescent Psychiatry and Mental Health|January 12, 2012
A systematic review of the safety information contained within the Summaries of Product Characteristics of medications licensed in the United Kingdom for Attention Deficit Hyperactivity Disorder. how does the safety prescribing advice compare with national guidance?Nicola Savill, Chris J BusheTherapeutic Advances in Psychopharmacology|August 29, 2013
Olanzapine long-acting injection: insights from an early case series in the UKDeirdre McGlennon, Chris J BushePageof 78